JAML and diabetic kidney disease: These findings suggest that therapeutic modulation of lipid metabolism through JAML/Sirt1 pathway inhibition may represent a promising strategy to mitigate lipid deposition, inflammatory indicators, prevent podocyte injury, and ultimately delay DKD progression (Kang et al., 2015).